Join
Live feed
·
PRReleasevia Quantisnow
Neurogene Inc. logo

Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

ByQuantisnow·Wall Street's wire, on your screen.
NGNE· Neurogene Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NGNE (Neurogene Inc.) and more on Quantisnow.